+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

United States Pain Management Therapeutics Market, Forecast 2022-2028, Industry Trends, Outlooks, Impact of COVID-19, Company Analysis

  • ID: 5562701
  • Report
  • March 2022
  • Region: United States
  • 180 Pages
  • Renub Research

FEATURED COMPANIES

  • Abbott Laboratories
  • Boehringer Ingelheim
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
United States Pain Management Therapeutics Market will reach US$ 12.55 Billion in 2028. Patients with acute and chronic pain has faced a crisis in the United States for years due to severe problems accessing sufficient care, resulting in considerable physical, emotional, and societal expenses. To treat pain caused by inflammation in reaction to tissue injury, chemical agents/pathogens (nociceptive pain), or nerve damage, a variety of pain management therapies are employed (neuropathic pain). Most gadgets and medications work by attaching to protein targets on cell membranes and altering the body's biochemical processes. Nonetheless, prescription opioids, heroin, and synthetic opioids have been linked to an alarming increase in overdose mortality during the last two decades.



U.S. Pain Management Therapeutics Industry will grow with 9.3% CAGR from 2021-2028


In recent years, because of the geriatric population in the United States, there has been an increase in pain management therapeutics. Furthermore, the rising preponderance of diseases such as cancer, diabetic neuropathy, osteoarthritis, and chronic arthritis and an increase in surgical procedures and healthcare spending are key factors driving the market for pain management therapeutics in the United States. Furthermore, rising healthcare awareness propels the global pain management medications market forward.

COVID-19 Outbreak Effect on Pain Management Therapeutics Industry in the United States:


Most industries, including the medical device industry, were affected by the COVID-19 pandemic. Patients who rely on exercise programs or physical therapy as a pain management regimen have been affected by nationwide lockdowns. Furthermore, numerous elective surgeries and in-person patient visits have been halted or postponed, increasing the demand for at-home pain therapy. Lockdown measures adopted by governments in many nations also hampered manufacturing activities. Furthermore, the supply chain was interrupted, resulting in raw material shortages. According to the publisher Report, the U.S. Pain Management Therapeutics Market Size was US$ 6.75 Billion in 2021.

By Pain Type, United States Pain Management Therapeutics Market Is Classified into Acute Pain and Chronic Pain:


The United States Pain Management Therapeutics Industry is divided into two categories in our report: Acute Pain and Chronic Pain. Acute pain occurs suddenly, whereas chronic pain lasts for a long time. Chronic pain is mainly caused by bone and joint aging, nerve damage, and injury. To treat or lessen the symptoms of these types of pain, a specific collection of medications is used. On the other hand, the pain process is complicated, and there is a range of medicines that provide relief by working on a variety of physiological mechanisms.

Pharmaceuticals Holds the Dominant Share In The Market:


Pharmaceuticals and devices are among the numerous forms of pain-relieving medications based on therapies, and each therapeutic operates in a slightly different way. Furthermore, the effectiveness of a pain-relieving medicine for a particular type of pain and the risk of adverse effects in a specific person determine the medication's selection. Pharmaceuticals, according to our research, have the largest market share. Furthermore, with technological advancements, the gadgets segment is likely to rise.

Device Insights of Pain Management Therapeutics Industry in the United States:


The neurostimulation category controls the significant market. The rising occurrence of neurological illnesses can be blamed for dominance. Furthermore, neurostimulators are essential in treating chronic pain, Parkinson's disease, epilepsy, movement disorders, and depression. In addition, the segment is expected to develop due to factors such as rising product demand, the launch of technologically sophisticated items, and the growing elderly population.

Aside from that, due to its broad applicability in pain management, surgical oncology, gynecology, cardiology & cardiac rhythm management, and cosmetology, radiofrequency ablation is predicted to increase at the quickest rate over the projection period. Radiofrequency ablation is more advantageous than open surgery in treating patients with numerous tumors, which drives up demand.

NSAIDs Segment Reports Foremost Market Share:


Our report studies the markets for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Anesthetics, Anticonvulsants, Anti-Migraine Agents, Antidepressants, Opioids, and Nonnarcotic Analgesics. According to our research, NSAIDs have the largest market share in the US pain management therapeutics industry. The substantial market share of NSAIDs is due to their availability as over-the-counter medications and inexpensive costs. Nonsteroidal anti-inflammatory medicines are also in high demand due to characteristics such as the convenience of use and fast pain alleviation (NSAIDs).

By Indication, Neuropathic Pain is projected to dominate the Indication Segment:


The somatosensory nerve system is damaged or afflicted, resulting in neuropathic pain. The majority of neuropathic pain is persistent. One instance of neuropathic pain is phantom limb syndrome. When a leg or an arm is severed due to an injury or sickness, the brain continues to receive pain signals through the nerves used to carry impulses from the missing limb. Pain is caused by nerve misfiring. Because neuropathic pain is chronic, pain-relieving drugs are given frequently, resulting in a significant revenue share.

Key Companies Insights:


Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline plc, Novartis International AG, Merck & Co., Inc., Abbott Laboratories, Johnson & Johnson, and Boehringer Ingelheim are among the prominent industry participants covered in the analysis. To increase their market position in the United States, significant corporations have attempted several strategic efforts, including technology innovation, partnerships, regional expansion, and mergers and acquisitions.

The publisher's latest report US Pain Management Therapeutics Industry, Forecast By Therapeutics (Pharmaceuticals, Devices), Devices (Electrical Stimulators, Radiofrequency Ablation, Analgesic Infusion Pumps, Neurostimulation), Drug Class (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Anesthetics, Anticonvulsants, Anti-Migraine Agents, Antidepressants, Opioids, Nonnarcotic Analgesics), Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Post-Operative Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Sprain/Strain, Acute Appendicitis and Others), Pain Type (Chronic Pain, Acute Pain), Companies (Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline plc, Novartis International AG, Merck & Co., Inc., Abbott Laboratories, Johnson & Johnson, and Boehringer Ingelheim) provides a detailed analysis of US Pain Management Therapeutics Industry.

Therapeutics - Market has been covered from 2 viewpoints:


1. Pharmaceuticals
2. Devices

Devices - Market has been covered from 4 viewpoints:


1. Electrical Stimulators
2. Radiofrequency Ablation
3. Analgesic Infusion Pumps
4. Neurostimulation

Drug Class - Market has been covered from 7 viewpoints:


1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
2. Anesthetics
3. Anticonvulsants
4. Anti-Migraine Agents
5. Antidepressants
6. Opioids
7. Nonnarcotic Analgesics

Indication - Market has been covered from 11 viewpoints:


1. Arthritic Pai
2. Neuropathic Pain
3. Cancer Pain
4. Chronic Back Pain
5. Post-Operative Pain
6. Migraine
7. Fibromyalgia
8. Bone Fracture
9. Muscle Sprain/Strain
10. Acute Appendicitis
11. Others

Pain Type - Market has been covered from 2 viewpoints:


1. Chronic Pain
2. Acute Pain

Company Insights:


  • Overview
  • Recent Development
  • Financial Insight

Companies Covered:


1. Eli Lilly and Company
2. Pfizer Inc.
3. GlaxoSmithKline plc
4. Novartis International AG
5. Merck & Co., Inc.
6. Abbott Laboratories
7. Johnson & Johnson
8. Boehringer Ingelheim
Frequently Asked Questions about the United States Pain Management Therapeutics Market

What is the estimated value of the United States Pain Management Therapeutics Market?

The United States Pain Management Therapeutics Market was estimated to be valued at $6.8 Billion in 2021.

What is the growth rate of the United States Pain Management Therapeutics Market?

The growth rate of the United States Pain Management Therapeutics Market is 9.3%, with an estimated value of $12.6 Billion by 2028.

What is the forecasted size of the United States Pain Management Therapeutics Market?

The United States Pain Management Therapeutics Market is estimated to be worth $12.6 Billion by 2028.

Who are the key companies in the United States Pain Management Therapeutics Market?

Key companies in the United States Pain Management Therapeutics Market include Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline plc, Novartis International AG, Merck & Co., Inc., Abbott Laboratories and Boehringer Ingelheim.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Boehringer Ingelheim
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.

1. Introduction2. Research Methodology3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. US Pain Management Therapeutics Market
6. Market Share - US Pain Management Therapeutics Market
6.1 By Therapeutics
6.2 By Devices
6.3 By Drug Class
6.4 By Indication
6.5 By Pain Type
7. Therapeutics - US Pain Management Therapeutics Market
7.1 Pharmaceuticals
7.2 Devices
8. Devices - US Pain Management Therapeutics Market
8.1 Electrical Stimulators
8.2 Radiofrequency Ablation
8.3 Analgesic Infusion Pumps
8.4 Neurostimulation
9. Drug Class - US Pain Management Therapeutics Market
9.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
9.2 Anesthetics
9.3 Anticonvulsants
9.4 Anti-Migraine Agents
9.5 Antidepressants
9.6 Opioids
9.7 Nonnarcotic Analgesics
10. Indication - US Pain Management Therapeutics Market
10.1 Arthritic Pain
10.2 Neuropathic Pain
10.3 Cancer Pain
10.4 Chronic Back Pain
10.5 Post-Operative Pain
10.6 Migraine
10.7 Fibromyalgia
10.8 Bone Fracture
10.9 Muscle Sprain/Strain
10.10 Acute Appendicitis
10.11 Others
11. Pain Type - US Pain Management Therapeutics Market
11.1 Chronic Pain
11.2 Acute Pain
12. Porter's Five Forces Analysis
12.1 Threat of New Entry
12.2 The Bargaining Power of Buyer
12.3 Threat of Substitution
12.4 The Bargaining Power of Supplier
12.5 Competitive Rivalry
13. Company Analysis
13.1 Eli Lilly and Company
13.1.1 Overview
13.1.2 Recent Development
13.1.3 Financial Insight
13.2 Pfizer Inc.
13.2.1 Overview
13.2.2 Recent Development
13.2.3 Financial Insight
13.3 GlaxoSmithKline plc
13.3.1 Overview
13.3.2 Recent Development
13.3.3 Financial Insight
13.4 Novartis International AG
13.4.1 Overview
13.4.2 Recent Development
13.4.3 Financial Insight
13.5 Merck & Co., Inc.
13.5.1 Overview
13.5.2 Recent Development
13.5.3 Financial Insigh
13.6 Abbott Laboratories
13.6.1 Overview
13.6.2 Recent Development
13.6.3 Financial Insight
13.7 Johnson & Johnson
13.7.1 Overview
13.7.2 Recent Development
13.7.3 Financial Insight
13.8 Boehringer Ingelheim
13.8.1 Overview
13.8.2 Recent Development
13.8.3 Financial Insight
List Of Figures:
Figure 01: United States - Pain Management Therapeutics Market (Billion US$), 2018 - 2021
Figure 02: United States - Forecast for Pain Management Therapeutics Market (Billion US$), 2022 - 2027
Figure 03: Therapeutics - Pharmaceuticals Market (Billion US$), 2018 - 2021
Figure 04: Therapeutics - Forecast for Pharmaceuticals Market (Billion US$), 2022 - 2027
Figure 05: Therapeutics - Devices Market (Billion US$), 2018 - 2021
Figure 06: Therapeutics - Forecast for Devices Market (Billion US$), 2022 - 2027
Figure 07: Devices - Electrical Stimulators Market (Million US$), 2018 - 2021
Figure 08: Devices - Forecast for Electrical Stimulators Market (Million US$), 2022 - 2027
Figure 09: Devices - Radiofrequency Ablation Market (Million US$), 2018 - 2021
Figure 10: Devices - Forecast for Radiofrequency Ablation Market (Million US$), 2022 - 2027
Figure 11: Devices - Analgesic Infusion Pumps Market (Million US$), 2018 - 2021
Figure 12: Devices - Forecast for Analgesic Infusion Pumps Market (Million US$), 2022 - 2027
Figure 13: Devices - Neurostimulation Market (Billion US$), 2018 - 2021
Figure 14: Devices - Forecast for Neurostimulation Market (Billion US$), 2022 - 2027
Figure 15: Drug Class - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (Billion US$), 2018 - 2021
Figure 16: Drug Class - Forecast for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (Billion US$), 2022 - 2027
Figure 17: Drug Class - Anesthetics Market (Billion US$), 2018 - 2021
Figure 18: Drug Class - Forecast for Anesthetics Market (Billion US$), 2022 - 2027
Figure 19: Drug Class - Anticonvulsants Market (Billion US$), 2018 - 2021
Figure 20: Drug Class - Forecast for Anticonvulsants Market (Billion US$), 2022 - 2027
Figure 21: Drug Class - Anti-Migraine Agents Market (Billion US$), 2018 - 2021
Figure 22: Drug Class - Forecast for Anti-Migraine Agents Market (Billion US$), 2022 - 2027
Figure 23: Drug Class - Antidepressants Market (Billion US$), 2018 - 2021
Figure 24: Drug Class - Forecast for Antidepressants Market (Billion US$), 2022 - 2027
Figure 25: Drug Class - Opioids Market (Billion US$), 2018 - 2021
Figure 26: Drug Class - Forecast for Opioids Market (Billion US$), 2022 - 2027
Figure 27: Drug Class - Nonnarcotic Analgesics Market (Billion US$), 2018 - 2021
Figure 28: Drug Class - Forecast for Nonnarcotic Analgesics Market (Billion US$), 2022 - 2027
Figure 29: Indication - Arthritic Pain Market (Billion US$), 2018 - 2021
Figure 30: Indication - Forecast for Arthritic Pain Market (Billion US$), 2022 - 2027
Figure 31: Indication - Neuropathic Pain Market (Billion US$), 2018 - 2021
Figure 32: Indication - Forecast for Neuropathic Pain Market (Billion US$), 2022 - 2027
Figure 33: Indication - Cancer Pain Market (Billion US$), 2018 - 2021
Figure 34: Indication - Forecast for Cancer Pain Market (Billion US$), 2022 - 2027
Figure 35: Indication - Chronic Back Pain Market (Billion US$), 2018 - 2021
Figure 36: Indication - Forecast for Chronic Back Pain Market (Billion US$), 2022 - 2027
Figure 37: Indication - Post-Operative Pain Market (Billion US$), 2018 - 2021
Figure 38: Indication - Forecast for Post-Operative Pain Market (Billion US$), 2022 - 2027
Figure 39: Indication - Migraine Market (Billion US$), 2018 - 2021
Figure 40: Indication - Forecast for Migraine Market (Billion US$), 2022 - 2027
Figure 41: Indication - Fibromyalgia Market (Billion US$), 2018 - 2021
Figure 42: Indication - Forecast for Fibromyalgia Market (Billion US$), 2022 - 2027
Figure 43: Indication - Bone Fracture Market (Million US$), 2018 - 2021
Figure 44: Indication - Forecast for Bone Fracture Market (Million US$), 2022 - 2027
Figure 45: Indication - Muscle Sprain/Strain Market (Million US$), 2018 - 2021
Figure 46: Indication - Forecast for Muscle Sprain/Strain Market (Million US$), 2022 - 2027
Figure 47: Indication - Acute Appendicitis Market (Million US$), 2018 - 2021
Figure 48: Indication - Forecast for Acute Appendicitis Market (Million US$), 2022 - 2027
Figure 49: Indication - Others Market (Billion US$), 2018 - 2021
Figure 50: Indication - Forecast for Others Market (Billion US$), 2022 - 2027
Figure 51: Pain Type - Chronic Pain Market (Billion US$), 2018 - 2021
Figure 52: Pain Type - Forecast for Chronic Pain Market (Billion US$), 2022 - 2027
Figure 53: Pain Type - Acute Pain Market (Billion US$), 2018 - 2021
Figure 54: Pain Type - Forecast for Acute Pain Market (Billion US$), 2022 - 2027
Figure 55: Eli Lilly and Company - Global Revenue (Billion US$), 2018 - 2021
Figure 56: Eli Lilly and Company - Forecast for Global Revenue (Billion US$), 2022 - 2027
Figure 57: Pfizer Inc. - Global Revenue (Billion US$), 2018 - 2021
Figure 58: Pfizer Inc. - Forecast for Global Revenue (Billion US$), 2022 - 2027
Figure 59: GlaxoSmithKline plc - Global Revenue (Billion US$), 2018 - 2021
Figure 60: GlaxoSmithKline plc - Forecast for Global Revenue (Billion US$), 2022 - 2027
Figure 61: Novartis International AG - Global Revenue (Billion US$), 2018 - 2021
Figure 62: Novartis International AG - Forecast for Global Revenue (Billion US$), 2022 - 2027
Figure 63: Merck & Co., Inc. - Global Revenue (Billion US$), 2018 - 2021
Figure 64: Merck & Co., Inc. - Forecast for Global Revenue (Billion US$), 2022 - 2027
Figure 65: Abbott Laboratories - Global Revenue (Billion US$), 2018 - 2021
Figure 66: Abbott Laboratories - Forecast for Global Revenue (Billion US$), 2022 - 2027
Figure 67: Johnson & Johnson - Global Revenue (Billion US$), 2018 - 2021
Figure 68: Johnson & Johnson - Forecast for Global Revenue (Billion US$), 2022 - 2027
Figure 69: Boehringer Ingelheim - Global Revenue (Billion US$), 2018 - 2021
Figure 70: Boehringer Ingelheim - Forecast for Global Revenue (Billion US$), 2022 - 2027
List Of Tables:
Table 01: United States Pain Management Therapeutics Market Share by Therapeutics (Percent), 2018 - 2021
Table 02: Forecast for - United States Pain Management Therapeutics Market Share by Therapeutics (Percent), 2022 - 2027
Table 03: United States Pain Management Therapeutics Market Share by Devices (Percent), 2018 - 2021
Table 04: Forecast for - United States Pain Management Therapeutics Market Share by Devices (Percent), 2022 - 2027
Table 05: United States Pain Management Therapeutics Market Share by Drug Class (Percent), 2018 - 2021
Table 06: Forecast for - United States Pain Management Therapeutics Market Share by Drug Class (Percent), 2022 - 2027
Table 07: United States Pain Management Therapeutics Market Share by Indication (Percent), 2018 - 2021
Table 08: Forecast for - United States Pain Management Therapeutics Market Share by Indication (Percent), 2022 - 2027
Table 09: United States Pain Management Therapeutics Market Share by Pain Type (Percent), 2018 - 2021
Table 10: Forecast for - United States Pain Management Therapeutics Market Share by Pain Type (Percent), 2022 - 2027
Note: Product cover images may vary from those shown
  • Eli Lilly and Company
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis International AG
  • Merck & Co., Inc.
  • Abbott Laboratories
  • Johnson & Johnson
  • Boehringer Ingelheim
Note: Product cover images may vary from those shown

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...